STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #402 by analyst upside · 2026-08-13
ZURA
Zura Bio Limited
Healthcare · Market Cap $554M · P/E 0x
ANALYST PRICE TARGET
+228.7%
implied upside to consensus target
Current Price $5.78
Consensus Target $19.0
Bull Target $26.0
Bear Target $11.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
0
Sell
0
52-Week Low $1.47
52-Week High $7.44
YTD Return +4.1%
FUNDAMENTALS
Market Cap $554M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.12
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.47
52-Week High $7.44
Current Price $5.78
Bear Target $11.0
Bull Target $26.0
● Now $5.78 ● Target $19.0
TRADING DATA
Avg Volume 1.1M
YTD Return +4.1%
Analyst Count 5
Consensus Buy
Upside to Target +228.7%
Last Updated 2026-08-13

ANALYST SUMMARY

Zura Bio Limited (ZURA) is currently trading at $5.78 with a Wall Street consensus price target of $19.0, implying potential upside of 228.7% over the next 12 months. 5 analysts currently cover ZURA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $26.0, while the most cautious has a target of $11.0.

ZURA operates in the Healthcare sector with a market capitalisation of $554M. The stock is up 4.1% year-to-date and is currently trading near the upper end of its 52-week range of $1.47 – $7.44.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZURA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital - Reiterated
Buy → Buy 2026-03-23 33% win rate (6 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-03-20 14% win rate (7 calls)
Wedbush ● Initiated
Outperform 2026-02-09 Building track record
Chardan Capital - Reiterated
Buy → Buy 2025-11-14 33% win rate (6 calls)
Clear Street ● Initiated
Buy 2025-11-13 Building track record
Chardan Capital - Reiterated
Buy → Buy 2025-09-30 33% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Neutral → Neutral 2025-08-19 31% win rate (48 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2025-08-15 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →